Profil
William Keun Chan Park is the founder of Theromics, Inc. He held the title of Chief Science Officer at the company, and his job functions included FOU (Founder) and CTO (Chief Technology Officer).
Postes actifs de Keun Chan Park
| Sociétés | Poste | Début |
|---|---|---|
Theromics, Inc.
 Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Theromics, Inc.
Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy. | Health Technology |